Kura Oncology price target raised to $38 from $36 at Wedbush

Wedbush raised the firm’s price target on Kura Oncology (KURA) to $38 from $36 and keeps an Outperform rating on the shares. The firm notes Ziftomenib at 600 mg QD dosing was approved in r/r NPM1m AML, ahead of the PDUFA date of November 30th. The approval was based on the KOMET-001 study.